These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 25441388)

  • 1. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
    Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
    J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
    Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
    Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
    Wu FF; Gao YJ; Pan C; Chen J; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco.
    Willis B; Ablin A; Weinberg V; Zoger S; Wara WM; Matthay KK
    J Clin Oncol; 1996 Jul; 14(7):2073-82. PubMed ID: 8683239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome.
    Howarth DM; Gilchrist GS; Mullan BP; Wiseman GA; Edmonson JH; Schomberg PJ
    Cancer; 1999 May; 85(10):2278-90. PubMed ID: 10326709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.
    Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience.
    Ehrhardt MJ; Humphrey SR; Kelly ME; Chiu YE; Galbraith SS
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):613-6. PubMed ID: 25171449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Langerhans cell histiocytosis mimicking molluscum contagiosum: A case series.
    Fernández Armenteros JM; Arco Huguet N; Sanmartin Novell V; Vilardell Villellas F; Velasco Sanchez A; Martró Català E; Martí Laborda RM; Soria Gili X
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27047. PubMed ID: 29528195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood Langerhans cell histiocytosis: a disease with many faces.
    Leung AKC; Lam JM; Leong KF
    World J Pediatr; 2019 Dec; 15(6):536-545. PubMed ID: 31456157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis.
    Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O;
    J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans cell histiocytosis in neonates.
    Minkov M; Prosch H; Steiner M; Grois N; Pötschger U; Kaatsch P; Janka-Schaub G; Gadner H
    Pediatr Blood Cancer; 2005 Nov; 45(6):802-7. PubMed ID: 15770639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood.
    Odame I; Li P; Lau L; Doda W; Noseworthy M; Babyn P; Weitzman S
    Pediatr Blood Cancer; 2006 Dec; 47(7):889-93. PubMed ID: 16276522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.